Dementia :: Alzheimer’s drugs ban in UK, NHS – NICE

National Institute for Clinical Excellence (NICE) has restricted the use of Alzheimer’s drugs in the National Health Service, recently.

NICE, a special health authority of the National Health Service that decides which medicines are offered in the NHS in England and Wales, refused to reveal those vital documents on the basis of which it reached a conclusion to ban the medication.

It concluded in its ruling that people suffering with mild and severe Alzheimer’s disease should not be prescribed Pfizer and Eisai’s Aricept, an oral medication used to treat Alzheimer’s disease, on the NHS. The agency also restricted the use of Novartis’s Exelon and Shire’s Reminyl, a drug also used for the treatment of mild to moderate Alzheimer?s disease, the most common form of dementia.

The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.

NICE produces guidance in three areas of health:

public health – guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector health technologies – guidance on the use of new and existing medicines, treatments and procedures within the NHS clinical practice – guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.


Leave a Comment